Two drug companies have agreed to a $54 million settlement in San Francisco’s opioid trial on Tuesday, just as closing arguments were set to begin.

Allergan, part of AbbVie, and Teva, both manufacturers of the prescription painkillers, will provide the city and county of San Francisco $34 million in cash payments and $20 million worth of the overdose reversal drug, Narcan. Closing arguments in the trial, which began on April 25 and has been livestreamed on the court’s website, continue on Tuesday against a third defendant, Walgreens.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]